Pulmonary Cell News Volume 3.27 | Jul 17 2014

ICAM-1 Targeted Nanogels Loaded with Dexamethasone Alleviate Pulmonary Inflammation
Investigators studied the potential of targeted nanogels as a drug delivery platform in vivo to alleviate acute pulmonary inflammation in animal model of lipopolysaccharide-induced lung injury. [PLoS One] Full Article

Transcriptome Profile Analysis of Saturated Aliphatic Aldehydes Reveals Carbon Number-Specific Molecules Involved in Pulmonary Toxicity
Scientists investigated the transcriptomic responses and identified specific molecular signatures of low-molecular-weight saturated aliphatic aldehydes (LSAAs). To evaluate the change in gene expression levels, A549 human alveolar epithelial cells were exposed to six LSAAs (propanal, butanal, pentanal, hexanal, heptanal, and octanal) for 48 hours. [Chem Res Toxicol] Abstract

Blockade of PDE4B Limits Lung Vascular Permeability and Lung Inflammation in LPS-Induced Acute Lung Injury
To investigate the mechanism of how PDE4B takes part in inflammatory response and the maintenance of vascular integrity, researchers established the experimental model of acute lung injury in vitro and in vivo. [Biochem Biophys Res Commun] Abstract

Peptide Regulation of Gene Expression and Protein Synthesis in Bronchial Epithelium
Investigators measured Ki67, Mcl-1, p53, CD79, and NOS-3 protein levels in the 1st, 7th, and 14th passages of bronchoepithelial human embryonic cell cultures. [Lung] Abstract

LUNG CANCER

Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, Nuclear Factor-kappa B, and Cell Cycle Progression in Non-Small Cell Lung Cancer
To test drug combinations that could improve the efficacy of erlotinib, researchers combined erlotinib with quinacrine, which inhibits the FACT (facilitates chromatin transcription) complex that is required for NF-kappaB transcriptional activity. In A549, H1975 and H1993 non-small cell lung cancer cells, this drug combination was highly synergistic, as quantified by Chou-Talalay combination indices, and slowed xenograft tumor growth. [Mol Cancer Ther] Abstract

Quantitative Proteomic Approach to Understand Metabolic Adaptation in Non-Small Cell Lung Cancer
Investigators carried out the proteomic analysis of two KRAS-mutated non-small cell lung cancer (NSCLC) cell lines and a non-tumoral bronchial cell line using an iTRAQ (isobaric Tags for Relative and Absolute Quantitation) approach combined with two-dimensional fractionation and MALDI-TOF/TOF mass spectrometry analysis. [J Proteome Res] Abstract

Evidence that RASSF1C Stimulation of Lung Cancer Cell Proliferation Depends on IGFBP-5 and PIWIL1 Expression Levels
The authors report that RASSF1C promotes lung cancer cell migration and enhances lung cancer cell tumor sphere formation. They also show that RASSF1C over-expression reduces the inhibitory effects of the anti-cancer agent, betulinic acid, on lung cancer cell proliferation. [PLoS One] Full Article

TNF-Related Apoptosis-Inducing Ligand Enhances Vinorelbine-Induced Apoptosis and Antitumor Activity in a Preclinical Model of Non-Small Cell Lung Cancer
The authors evaluated the antitumor effects of the two drugs (TRAIL and NVB alone or in combination) by inducing apoptosis in vitro and in vivo. Using the human non-small cell lung cancer cell line and a BALB/c nude mice model, they observed the cell viability, cell apoptosis and cell proliferation. [Oncol Rep] Abstract

MicroRNA-1290 Promotes Asiatic Acid-Induced Apoptosis by Decreasing BCL2 Protein Level in A549 Non-Small Cell Lung Carcinoma Cells
Investigators identified an important regulator of asiatic acid-induced cell death, microRNA-1290, which sensitizes cells to asiatic acid-induced cytotoxicity and negatively regulates BCL2 expression. [Oncol Rep] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

Alberto Chiappori, Julien Sage, and E. Alejandro Sweet-Cordero Receive LUNGevity Foundation 2014 Targeted Therapeutics Awards for Lung Cancer Research
LUNGevity Foundation announced the 2014 awardees of its Targeted Therapeutics for Translational Lung Cancer Research program. Each of the three multi-year awards ranges from $100,000 to $200,000 for the first year and is renewable in that amount, based on research progress, for each subsequent year. [LUNGevity Foundation] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the pulmonary cell community.

Postdoctoral Fellow – Mechanisms of Lung Alveoli Epithelial Repair (University of Illinois Chicago College of Medicine)

Postdoctoral Research Associate – Lung Development Research (Women and Infants Hospital of Rhode Island)

Postdoctoral Research Trainee – Lung Injury and Epithelial Repair (University of Tennessee Health Science Center)

Director, US Medical Affairs – Lung Job (Celgene Corporation)

Postdoctoral Scholar – Molecular Mechanisms of Lung Cancer, Lung Regeneration and Lung Development (University of California – San Francisco)

Primary Cell Culture Position – Heart/Lung Disease (Paramount Recruitment)

Postdoctoral Position – Molecular and Cell Biology (Cornell University)

Postdoctoral Fellow – Lung Biology and Genomics (Harvard University)

Scientist – Pluripotent Stem Cell Biology Endoderm Lineages (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.